Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Carissa Summa

Dermatology Estero, FL Doctor of Osteopathy

NPI 1376614669 CMS profile 153397

10200 Arcos Ave Ste 201, Estero, FL 33928

Open in the dashboard

General payments

$2,740

121 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carissa Summa of Estero, FL is reported in the CMS Open Payments database as having received $2,740 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $771 32
2024 General $1,095 58
2023 General $640 24
2022 General $234 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carissa Summa
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Carissa Summa were reported at $771. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Carissa Summa Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $234 $514 $143–$1,391 $149
2023 $640 $607 $159–$1,674 $160
2024 $1,095 $751 $204–$1,903 $164
2025 $771 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $534 25 payments
  2. Organogenesis Inc. $401 22 payments
  3. Lilly USA, LLC $372 14 payments
  4. Pfizer Inc. $279 9 payments
  5. AbbVie, Inc. $186 10 payments
  6. Novartis Pharmaceuticals Corporation $185 8 payments
  7. Sun Pharmaceutical Industries Inc. $154 4 payments
  8. Genzyme Corporation $137 5 payments
  9. Galderma Laboratories, L.P. $85 5 payments
  10. Dermavant Sciences, Inc. $81 3 payments
  11. Other $327 16 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,356 117 payments
  2. Education $384 4 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $505 23 payments
  2. TALTZ $372 14 payments
  3. CIBINQO $279 9 payments
  4. DUPIXENT $166 6 payments
  5. COSENTYX $160 7 payments
  6. OLUMIANT $152 6 payments
  7. SIMPONI ARIA $144 16 payments
  8. STELARA $144 16 payments
  9. SIMPONI $144 16 payments
  10. EBGLYSS $128 4 payments
  11. Other $1,484 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,185

Median for Dermatology: 534

Drug cost

$40,219

Median for Dermatology: $67,151

Branded share of claims

6.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vtama Tapinarof Brand 12 $16,621
Clobetasol Propionate Generic 94 $4,147
Fluorouracil Generic 50 $3,147
Fluocinonide Generic 89 $2,785
Triamcinolone Acetonide Generic 302 $2,558
Clindamycin Phosphate Generic 60 $2,260
Ketoconazole Generic 148 $2,028
Metronidazole Generic 33 $1,471
Gentamicin Sulfate Generic 26 $863
Ammonium Lactate Generic 38 $666

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $192
$192 — —
DUPIXENT
  • GENZYME CORPORATION $107
  • Regeneron Healthcare Solutions, Inc. $44
$151 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $90
$90 — —
TALTZ
  • Lilly USA, LLC $63
$63 — —
VTAMA
  • Dermavant Sciences, Inc. $60
$60 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record